BOONE, N.C., July 20, 2026
Fuse Oncology has unveiled FuseRx, an innovative AI-powered prescribing and treatment-intent solution designed to streamline workflows across radiation oncology and accelerate the journey from patient consultation to treatment. Officially introduced at the 68th AAPM Annual Meeting & Exhibition 2026, FuseRx serves as the cornerstone of the company’s structured AI platform by connecting consultation, simulation, treatment planning, and therapy delivery within a single intelligent workflow. The platform enables radiation oncologists to create structured treatment intent, including simulation orders, prescriptions, target definitions, organ-at-risk objectives, and supporting clinical documentation, through one guided interface. By replacing fragmented paper-based and PDF workflows with a fully digital platform featuring automated validation, configurable safety checks, audit trails, and standardized templates, FuseRx is designed to reduce delays, improve workflow efficiency, and support faster treatment initiation. The launch reflects the growing adoption of artificial intelligence and workflow automation in oncology care to improve clinical decision-making while enhancing operational performance across cancer treatment centers.
AI Platform Streamlines Radiation Oncology Workflow
At the heart of FuseRx is a structured AI-enabled clinical workflow that simplifies treatment planning from the moment a patient consultation begins. Physicians can develop comprehensive treatment plans using standardized templates while configuring institution-specific protocols, prescriptions, simulation requests, and treatment goals within a unified platform. Built-in validation engines, configurable safety rules, and hard-stop verification mechanisms help reduce documentation errors while maintaining consistency throughout the treatment process. The platform also includes a complete change-request audit trail, providing greater transparency and supporting regulatory compliance. By integrating all treatment planning activities into one digital environment, FuseRx eliminates many of the manual, repetitive administrative tasks that traditionally slow radiation oncology workflows. The result is a more efficient consult-to-treatment pathway that enables clinicians to focus more directly on patient care while reducing operational complexity for multidisciplinary oncology teams.
Evidence-Based Decision Support Enhances Personalized Care
A key differentiator of FuseRx is its ability to integrate evidence-based clinical pathways directly into physician workflows. Building on Fuse Oncology’s strategic collaboration with the American College of Radiation Oncology (ACRO), the platform incorporates ACROPath® clinical pathways, allowing physicians to access standardized treatment recommendations while preserving independent clinical judgment. The integration helps promote guideline-concordant cancer care, reduces unnecessary variation in treatment planning, and supports consistent decision-making at the point of prescribing. FuseRx also operates seamlessly with S!GNAL and FuseDocs, two additional components of the Fuse Oncology ecosystem, creating a unified patient record that maintains structured clinical data from initial consultation through treatment completion. This integrated approach supports improved collaboration between radiation oncologists, physicists, dosimetrists, and clinical staff while enabling more efficient coordination throughout the cancer treatment process.
Advertisement
Fuse Oncology Advances AI-Driven Cancer Care Innovation
The launch of FuseRx reinforces Fuse Oncology’s mission to transform radiation oncology through intelligent digital technologies that reduce administrative burden and accelerate patient access to treatment. As cancer centers continue adopting AI-powered healthcare solutions, platforms capable of integrating clinical documentation, treatment planning, workflow automation, and decision support have become increasingly important for improving efficiency without compromising patient safety. FuseRx represents another significant advancement in digital oncology, enabling healthcare providers to standardize workflows, strengthen quality assurance, and improve treatment coordination across the entire radiation therapy continuum. By combining artificial intelligence, structured clinical data, workflow automation, and evidence-based treatment pathways, Fuse Oncology is helping redefine modern radiation oncology practice while supporting the broader evolution of precision cancer care. The introduction of FuseRx positions the company at the forefront of AI-enabled oncology workflow innovation, offering healthcare organizations a scalable platform designed to improve both clinical efficiency and patient outcomes.
Source: Fuse Oncology Press release
